argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
argenx presented new clinical, long-term and real-world data for VYVGART in myasthenia gravis and CIDP at the 2026 AANEM and MGFA meetings. Key findings include deepening ocular MG benefit in ADAPT OCULUS, sustained one-year efficacy in antibody-negative MG from ADAPT SERON, and real-world evidence from more than 1,100 U.S. MG patients showing earlier treatment yields greater improvement. CIDP data reinforce VYVGART Hytrulo's long-term safety beyond five years, a 71.5% reduction in grip-strength deterioration risk, and 87% retention after a one-week IVIg switch.
Key figures
- Cidp incat 0 or 1
- approximately 40% of responding participants
- Real world mg patients
- 1100
- Seron mg adl improvement
- approximately 5 points through Week 52
- Ivig switch retention 12wk
- 87%
- Cidp grip strength rr reduction
- 71.5% (hazard ratio 0.285)
- Early treatment mg adl reduction
- 4.7 points (treated within 1 year) vs 3.5 points (treated >3 years after diagnosis)
- Cidp treatment naive response rate
- 87.5%
- Mg adl improvement ocular achr positive
- -4.5 to -6.8 points
- Mg adl improvement ocular triple seronegative
- -2.7 to -4.5 points
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.